Ownership and insider activity for Evolus, Inc. (EOLS): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Evolus, Inc. is a performance beauty enterprise that furnishes the United States market with medical aesthetic solutions for healthcare professionals and their patients. A key product in its portfolio is Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation. This product is specifically designed for adults seeking the temporary smoothing of moderate to severe glabellar (frown) lines. Founded in 2012, Evolus, Inc.
Price
| Price | $7.99 |
| Market Cap | $526M |
| Exchange | NASDAQ |
| Country | US |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 0 | 0 | $93.2M | $109.9M | $102.6M | $146.3M | $53.9M | $62.8M | $87.0M | $53.8M |
| Short-term Investments | 0 | 0 | 0 | $19.9M | $5.0M | 0 | 0 | 0 | 0 | 0 |
| Receivables | 0 | $72.6M | 0 | $10.7M | $9.7M | $14.7M | $22.4M | $30.5M | $47.7M | $54.7M |
| Inventory | 0 | 0 | 0 | $6.4M | $3.4M | $1.8M | $18.9M | $11.0M | $12.2M | $27.0M |
| Total Current Assets | $211000 | $72.8M | $94.3M | $152.2M | $127.6M | $178.8M | $100.8M | $112.4M | $151.3M | $142.9M |
| Property, Plant & Equipment | 0 | 0 | 0 | $5.0M | $4.7M | $4.1M | $4.6M | $7.8M | $10.4M | $12.5M |
| Goodwill | $21.2M | $21.2M | $21.2M | $21.2M | $21.2M | $21.2M | $21.2M | $21.2M | $21.2M | $21.2M |
| Intangible Assets | $56.1M | $56.1M | $56.1M | $59.6M | $55.3M | $50.6M | $48.6M | $47.1M | $48.8M | $48.0M |
| Total Assets | $77.5M | $152.2M | $171.8M | $240.4M | $209.1M | $257.5M | $178.0M | $189.0M | $232.6M | $225.9M |
| Accounts Payable | $2.9M | $445000 | $1.6M | $5.8M | $9.6M | $6.1M | $8.9M | $4.3M | $9.2M | $23.4M |
| Short-term Debt | $59.8M | $211.3M | 0 | 0 | $93.5M | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $63.3M | $212.7M | $5.3M | $24.4M | $180.2M | $57.7M | $46.5M | $48.3M | $63.0M | $75.3M |
| Long-term Debt | 0 | 0 | $16.9M | $91.5M | $40.5M | $71.2M | $71.9M | $120.4M | $121.5M | $146.1M |
| Total Liabilities | $84.6M | $227.8M | $87.5M | $161.0M | $282.0M | $175.6M | $159.5M | $209.7M | $227.0M | $249.0M |
| Retained Earnings | -$66.8M | -$75.5M | -$123.0M | -$213.1M | -$376.1M | -$422.9M | -$497.3M | -$559.0M | -$609.4M | -$661.0M |
| Total Equity | -$7.1M | -$75.5M | -$123.0M | $79.5M | -$73.0M | $81.9M | $18.5M | -$20.7M | $5.5M | -$23.1M |
| Total Debt | $59.8M | $211.3M | $16.9M | $96.5M | $138.3M | $74.7M | $74.4M | $126.5M | $130.0M | $155.0M |
| Net Debt | $59.8M | $211.3M | -$76.3M | -$33.3M | $30.8M | -$71.5M | $20.5M | $63.7M | $43.0M | $101.2M |
| Working Capital | -$63.1M | -$139.9M | $89.1M | $127.8M | -$52.6M | $121.1M | $54.3M | $64.1M | $88.4M | $67.6M |
Financial Health
| Debt / Equity | -5.33 |
| Current Ratio | 1.70 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -1.94 |
Profitability
| Return on Equity | 123.11% |
| Return on Invested Capital | -15.27% |
| Return on Assets | -13.84% |
| Gross Margin | 66.25% |
| Operating Margin | -7.33% |
| Net Margin | -10.85% |
Related companies: AUTL · CBLL · EHAB · KIDS · KMDA · NGNE · QSI
Explore sector: Healthcare · Drug Manufacturers - Specialty & Generic
More sections of EOLS: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks